Diazoxide for Severe or Recurrent Neonatal Hypoglycemia: A Randomized Clinical Trial

Area of Science:

• Neonatal Medicine
• Pediatric Endocrinology
• Clinical Pharmacology

Background:

• Neonatal hypoglycemia is a significant cause of neurodevelopmental impairment.
• Evidence guiding the treatment of neonatal hypoglycemia is limited.
• Severe or recurrent neonatal hypoglycemia requires effective therapeutic strategies.

Purpose of the Study:

• To assess if early, low-dose oral diazoxide effectively reduces the time to resolution of severe or recurrent neonatal hypoglycemia.
• To evaluate the impact of diazoxide on secondary outcomes, including blood glucose monitoring and feeding milestones.

Main Methods:

• A 2-arm, placebo-controlled randomized clinical trial involving 75 neonates (37.6 weeks' gestation) with severe or recurrent hypoglycemia.
• Participants received either oral diazoxide (5 mg/kg loading, 1.5 mg/kg maintenance) or placebo.
• Primary outcome: time to hypoglycemia resolution; secondary outcomes: blood glucose tests, hypoglycemia episodes, duration, feeding, and IV fluid weaning.

Main Results:

• Early diazoxide treatment did not significantly reduce the primary time to hypoglycemia resolution (AHR, 1.39; 95% CI, 0.84-2.23).
• However, diazoxide significantly reduced hypoglycemia duration (ARGM, 0.18), episodes (ACR, 0.32), blood glucose tests (ACR, 0.63), and time to enteral feeding and IV fluid weaning.
• Only 6% of diazoxide-treated neonates had hypoglycemia post-dose versus 53% in the placebo group.

Conclusions:

• Low-dose oral diazoxide for neonatal hypoglycemia did not shorten the primary resolution time but improved several key secondary outcomes.
• Diazoxide demonstrated a significant reduction in hypoglycemia duration, frequency, and monitoring needs.
• The findings suggest potential benefits of early diazoxide in managing neonatal hypoglycemia, particularly regarding clinical stability and resource utilization.